Fc fusion biologics for autoimmune disease and cancer
Raised to date
$16.3M
of $21M offered across 2 Form D filings
Gliknik Inc. is a pioneering biopharmaceutical company that specializes in the development of innovative biologics aimed at treating cancer and autoimmune disorders. The company's unique approach to drug development sets it apart in the biotech industry, as it seeks to create more effective and accessible alternatives to existing treatments.
Gliknik's distinct approach to biologic drug development is focused on maintaining full control over their clinical development pipeline, ensuring high-quality and innovative solutions for immune disorder treatment.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Aug 21, 2025 | Security to be acquired | $11M/ $15M | Form D |
| Jan 24, 2025 | Security to be acquired | $5.3M/ $6M | Form D/A |
Biologics
GL-2045 is a recombinant Fc fusion protein developed to emulate the therapeutic effects of intravenous immunoglobulin (IVIG), providing a potentially more effective option for treating various autoimmune diseases.
Built for
Patients with autoimmune disorders
